ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Eli Lilly and Co

Eli Lilly and Co (LLY)

918.52
-2.97
(-0.32%)
Closed September 23 4:00PM
921.356
2.84
( 0.31% )
Pre Market: 9:25AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
921.356
Bid
-
Ask
-
Volume
73,673
0.00 Day's Range 0.00
516.57 52 Week Range 972.53
Market Cap
Previous Close
918.52
Open
-
Last Trade
10
@
921.335
Last Trade Time
09:25:57
Financial Volume
-
VWAP
-
Average Volume (3m)
3,312,299
Shares Outstanding
950,425,778
Dividend Yield
0.56%
PE Ratio
166.59
Earnings Per Share (EPS)
5.51
Revenue
34.12B
Net Profit
5.24B

About Eli Lilly and Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology. Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Indianapolis, Indiana, USA
Founded
-
Eli Lilly and Co is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker LLY. The last closing price for Eli Lilly was $918.52. Over the last year, Eli Lilly shares have traded in a share price range of $ 516.57 to $ 972.53.

Eli Lilly currently has 950,425,778 shares outstanding. The market capitalization of Eli Lilly is $872.99 billion. Eli Lilly has a price to earnings ratio (PE ratio) of 166.59.

Eli Lilly (LLY) Options Flow Summary

Overall Flow

Bullish

Net Premium

14M

Calls / Puts

283.81%

Buys / Sells

98.48%

OTM / ITM

113.23%

Sweeps Ratio

0.00%

LLY Latest News

Lilly's Kisunlaβ„’ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease

Lilly's Kisunlaβ„’ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease PR Newswire INDIANAPOLIS, Sept. 24, 2024 Japan is the second major market where...

FDA Approves Lilly's EBGLYSSβ„’ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis

FDA Approves Lilly's EBGLYSSβ„’ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis PR Newswire INDIANAPOLIS, Sept. 13, 2024 EBGLYSS provides a...

Lilly expands manufacturing footprint in Ireland with $1.8 billion investment

Lilly expands manufacturing footprint in Ireland with $1.8 billion investment PR Newswire INDIANAPOLIS, Sept. 12, 2024 Company ups manufacturing investment in Limerick by $1 billion; unveils new...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.114-0.120762734831922.47939.86902.33737056916.86947285CS
4-30.214-3.17517366037951.57972.488932737082925.32317408CS
1219.5562.16855178532901.8972.53747.553312299888.80338295CS
26151.08619.6146805666770.27972.53718.32939786846.16522301CS
52368.82666.7522125495552.53972.53516.573082854739.30739119CS
156689.306297.050635639232.05972.53220.22995536477.13053557CS
260806.996705.662819168114.36972.53101.363260064336.47597465CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AACTAres Acquisition Corporation II
$ 10.80
(0.00%)
0
AAC.UAres Acquisition Corporation
$ 10.81
(0.00%)
0
AACAres Acquisition Corporation
$ 10.79
(0.00%)
0
AAAlcoa Corporation
$ 34.23
(0.00%)
95.53k
AAgilent Technologies
$ 139.79
(0.00%)
110.51k
AACTAres Acquisition Corporation II
$ 10.80
(0.00%)
0
AAC.UAres Acquisition Corporation
$ 10.81
(0.00%)
0
AACAres Acquisition Corporation
$ 10.79
(0.00%)
0
AAAlcoa Corporation
$ 34.23
(0.00%)
95.53k
AAgilent Technologies
$ 139.79
(0.00%)
110.51k
NIONIO Inc
$ 5.32
(0.00%)
5.85M
HEHawaiian Electric Industries
$ 10.90
(0.00%)
4.77M
BABAAlibaba Group Holding Limited
$ 90.09
(0.00%)
3.63M
SMARSmartsheet Inc
$ 52.09
(0.00%)
2.39M
VALEVale SA
$ 10.40
(0.00%)
1.92M

LLY Discussion

View Posts
TechandBio TechandBio 2 days ago
Wonder if Lily Buys SMMT.
$LLY
πŸ‘οΈ0
DewDiligence DewDiligence 4 weeks ago
LLY offers Zepbound in_single-use_vials_at_sharply_reduced_pricesβ€”(yesterday’s news):

https://www.nytimes.com/2024/08/27/well/eli-lilly-zepbound-price.html On Tuesday, Eli Lilly announced that it would start selling low doses of its weight-loss drug Zepbound in vials… β€” at a far lower price than its pens, which come with pre-filled doses. These vials will be made available only through LillyDirect, a telehealth platform the company launched in January (https://investor.lilly.com/news-releases/news-release-details/lilly-launches-end-end-digital-healthcare-experience-through ).

…The vials are significantly cheaper than Zepbound pens, which cost just over $1,000 a month without insurance. A month’s supply of the 2.5-milligram dose will cost $399, and a month’s worth of the five-milligram dose will cost $549.

… The company will offer vials with only the two lowest doses of Zepbound. Many patients stay on a five milligram dose… but some gradually increase their dose, up to a maximum of 15 milligrams. Any patient interested in taking more than the five-milligram dose would have to transition to the pens.

…the move could help Lilly regain customers who are currently getting compounded tirzepatide, which typically costs between roughly $250 and $450 a month. Why would anyone want a compounded formulation of tirzepatide derived from Chinese API when they can get the real thing from LLY at close to the same price?
πŸ‘οΈ0
Monksdream Monksdream 1 month ago
LLY new 52=week high
πŸ‘οΈ0
EnchantedTitan62 EnchantedTitan62 1 month ago
To quote Areosmith ' I'm back in the saddle again' . 💰
πŸ‘οΈ0
EnchantedTitan62 EnchantedTitan62 1 month ago
In the green premarket again. 🍷
πŸ‘οΈ0
EnchantedTitan62 EnchantedTitan62 1 month ago
Bought back in at open today. 🍷
πŸ‘οΈ0
EnchantedTitan62 EnchantedTitan62 1 month ago
In regards to new a pharma product.
πŸ‘οΈ0
Zardiw Zardiw 2 months ago
$LLY Chart from #DDAmanda - #1 Stock Screener :



Z
πŸ‘οΈ0
EnchantedTitan62 EnchantedTitan62 2 months ago
Just sold my LLY shares. Wonderful way to ease into the weekend. Good luck to everyone today.
πŸ‘οΈ0
EnchantedTitan62 EnchantedTitan62 2 months ago
Added @ $866.29
πŸ‘οΈ0
EnchantedTitan62 EnchantedTitan62 2 months ago
Going to be another green day.
πŸ‘οΈ0
EnchantedTitan62 EnchantedTitan62 2 months ago
I don't think they have sales in Europe yet, that'll change. 💰💰💰
πŸ‘οΈ0
EnchantedTitan62 EnchantedTitan62 2 months ago
Uh, probably not .
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
LLY new 52=week high
πŸ‘οΈ0
EL Sueno EL Sueno 2 months ago
Let's go fans 1000.00!!!
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
LLY new 52 week high
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
LLY new 52 week high
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
LLY 10Q due 4/30
Next day setttlement begins 5/28
πŸ‘οΈ0
north40000 north40000 7 months ago
FDA advises LLY it wants AdCom meeting. Portends delay. Meanwhile NVO CEO was interviewed on CNBC-TV this morning, repeats NVO’s PR warning dated in January 2024 that it will not have manufacturing capacity to fill demand for its weight loss drug until 2006(?).
πŸ‘οΈ0
Alfonz66 Alfonz66 7 months ago
Sell now boys you had a great run
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
LLY new 52 week high
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
LLY new 52 week high

πŸ‘οΈ0
oldstocks oldstocks 7 months ago
Eli Lilly was investigating Talampanel prior to 2010

For the treatment of epilepsy, malignant gliomas and ALS
development codes LY-300164 , LY300164
results from the trial for ALS have been found negative
Talampanel is not currently under development.
It showed effectiveness for epilepsy in clinical trials but its development was suspended due to its poor pharmacokinetic profile, namely a short terminal half-life (3 hours) that necessitated multiple doses per day.
RespireRx Pharmaceuticals $ RSPI a little unknown company KRM–II–81 has shown promising results for Epilepsy.
Has fully suppressed the epileptiform activity in the excised brain tissue from a 19-year-old patient with pharmaco-resistant epilepsy.
πŸ‘οΈ0
ralphey ralphey 7 months ago
I bought Lilly about a year ago based on Mounjaro and knowing it was going to be a success. I am a FAmily Doc who has done bariatric medicine for 30 years. Zepbound definitely is inducing more weight loss than Ozempic (Wegovy) but I am getting concerned over the number of patients that are stopping zepbound / Mounjaro due to side effects, seems a lot more than on Ozempic ( Wegovy) .
πŸ‘οΈ0
Monksdream Monksdream 8 months ago
Incredible, isn’t it
What gets me about these social media bozos is they actually believe they will become Boca Raton rich by day trading sub $1 stocks
Because they are incapable of researching companies
🌈 1 🍆 1
vinsterr vinsterr 8 months ago
800$ tomorrow?
πŸ‘οΈ0
Monksdream Monksdream 8 months ago
LLY new 52=week high
πŸ‘οΈ0
Monksdream Monksdream 8 months ago
LLY new 52 week high
πŸ‘οΈ0
Monksdream Monksdream 8 months ago
LLY new 52 week high
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
LLY new 52 week high
🍆 1
lvhd lvhd 11 months ago
Shorted at 625.
πŸ‘οΈ0
golfndude golfndude 11 months ago
Great news on their new diabetes drug.
πŸ‘οΈ0
peanutz peanutz 11 months ago
Looking for the bottom ,not yet :)
πŸ‘οΈ0
Monksdream Monksdream 11 months ago
LLY new 52 week high
πŸ‘οΈ0
TRUSTUNITS1000000 TRUSTUNITS1000000 12 months ago
Amazing financials
πŸ‘οΈ0
TRUSTUNITS1000000 TRUSTUNITS1000000 12 months ago
Billionaires dream a while back, speculating
πŸ‘οΈ0
TRUSTUNITS1000000 TRUSTUNITS1000000 12 months ago
Interesting company
πŸ‘οΈ0
TRUSTUNITS1000000 TRUSTUNITS1000000 12 months ago
Wowwwwwww
πŸ‘οΈ0
TRUSTUNITS1000000 TRUSTUNITS1000000 12 months ago
Knew this company from the 80 ssssss
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
LLY new 52 week high
πŸ‘οΈ0
lvhd lvhd 1 year ago
Who is pumping?
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
LLY new 52 week high
πŸ‘οΈ0
1jas 1jas 1 year ago
anyone here, hear enzc announced they now have a CURE for hiv/aids clone 3, yesterday on accesswire and yahoo finance.
πŸ‘οΈ0
1jas 1jas 1 year ago
anyone here, hear enzc announced they now have a CURE for hiv/aids clone 3, yesterday on accesswire and yahoo finance.
πŸ‘οΈ0
1jas 1jas 1 year ago
anyone here, hear enzc announced they now have a CURE for hiv/aids clone 3, yesterday on accesswire and yahoo finance.
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
LLY new 52 weewk high
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
LLY new 52 week high
πŸ‘οΈ0
Alex2365 Alex2365 1 year ago
RSI Moving Average Bullish Cross Over + Gap up with jump in volume.
Check out at - https://www.stockaio.com/US/ai/Stock/LLY/MovingAverage
πŸ‘οΈ0
kingjoe kingjoe 3 years ago
OTCSC nice post as always.

Let's hope this gets their attention.
πŸ‘οΈ0
OTCShotCaller OTCShotCaller 3 years ago
RGBP Is A FAR GREATER Fit Than ENZC And Here's Why!


# 1 RGBP has (24+) Disruptive Biotech Patents worth $$ BILLIONS; ENZC has only two (2).

https://patents.google.com/?inventor=David+Koos&sort=new
https://patents.justia.com/assignee/regen-biopharma-inc
https://www.otcmarkets.com/filing/html?id=15088630&guid=dk3wkKwg3iFaJth


# 2 Eli Lilly had prior collaborative arrangement with RGBP with joint I.P. claim on NR2F6 for developing an mRNA Cancer Vaccine

https://www.biospace.com/article/releases/regen-biopharma-enters-into-open-innovation-drug-discovery-program-agreement-with-eli-lilly-/


# 3 Eli Lilly-Curevac 2017 Partnership to develop mRNA Cancer Vaccine FAILED Ending June 2020 due to Curevac's faulty research data. Lilly lost $100 Million in shared development costs. Merger/Acquisition with RGBP is the shortest path to getting back on track!


# 4 Licensing of (1) Patent with (2) INDs (New Drug Applications) for treating pancreatic & colon cancer by mRNA Vaccine; The Future of Medicine

https://www.aamc.org/news-insights/mrna-technology-promises-revolutionize-future-vaccines-and-treatments-cancer-infectious-diseases


# 5 RGBP is in league with Big Pharmas developing mRNA Cancer Vaccines that Eli Lilly clearly wants to be included in, especially in the wake of their failed relationship with Curevac. It is a Trillion Dollar Market!

https://www.ventureradar.com/keyword/Cancer%20Vaccines


# 6 FDA Patent Approval

https://newsinvasion24.com/regen-biopharma-inc-otcmkts-rgbp-gets-approval-for-cancer-vaccine-patent/


# 7 Partnership:Oncology Pharma Paid $1M for Patent Licensing; will now Post Quarterly Revenues for 15 Years


# 8 Certification Audit of RGBP by BRG completed 11/15/21. This is indicative of an Industry Standard Merger/Acquisition


#9 On 4/27/21 CEO files Acquisition Intent with 8K

https://www.otcmarkets.com/filing/conv_pdf?id=14894907&guid=55ywkew26hwfJth


Opinion ONLY

Be well and prosper...
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock